The new report covers the total addressable market (TAM), market penetration, opportunity, and demand for Emerging Isotope is forecasted from 2020 to 2029.
LEWES, DELAWARE, UNITED STATES, July 21, 2022 /EINPresswire.com/ -- “Emerging Isotopes Pipeline Analysis and Global Market – Forecast to 2029” gives comprehensive insights on the various emerging isotope-based candidates being developed for both diagnosis as well as treatment of various cancers and non-cancer indications. The report covers marketed products details (Lutathera and Pluvito) and also candidates that are in various phases of development (Preclinical, Phase 1, Phase 2 & Phase 3). The pipeline focuses on diagnostic isotopes (Ga-68, Zr-89, Cu-64 and Pb-203) and therapeutic isotopes, (Ac-225, Pb-212, At-211, Ra-223, Th-227, Lu-177, Y-90, Re-188, Re-186, Cu-67, and Ho-166).In case of Lu-177, Ga-68, Zr-89 and Cu-64, the report covers the patient population, treatment cost, total addressable market and penetration analysis for GEP-NET, Prostate cancer and Renal cancer. The pipeline analysis covers detailed analysis of name of candidates, list of companies, universities, and hospitals that are developing these agents, phase of development, nature of molecule, targets, and indications.
This report enables Pharmaceutical/Biotech companies, Academic institutes, Individual researchers, Investors, Medical technology companies, Service providers and other associated stake holders to identify and analyze the available licensing/collaborative commercial opportunities in the emerging isotopes global market. The report also provides strategic insights on some of the molecules which will eventually be launched in the next few years.
Market Analysis
In market analysis, global GEP-NET, Prostate cancer and Renal cancer market are indicated along with the Ga-68, Cu-64 and Zr-89 diagnostics market, and Lu-177, therapy market size, eligible patients pool, total addressable market (TAM), market penetration, opportunity and demand for Emerging Isotope is forecasted from 2020 to 2029.
Emerging Isotopes related deals analysis.
Global, N.A., Europe, APAC and RoW prevalence rates (GEP-NET, Prostate and Renal cancer).
Pipeline Analysis
Pipeline Analysis based Isotopes
Pipeline Analysis based on indications
Pipeline analysis based on targets
Pipeline analysis based on leading players
Key Players Analysis
The key player’s analysis section provides an in-depth understanding of various companies working on Emerging Isotopes and their pipelines with development phase as well as understanding partnering strategies such as deals entered by the company.
Key players overview
Key players Pipeline data (Pre-clinical, Phase 1, Phase 2 & Phase 3)
Key players deals (collaborations, partnership, licensing agreements, grants, funding etc.,)
“Emerging Isotopes Pipeline Analysis and Global Market – Forecast to 2029” gives comprehensive insights on the various emerging isotope based candidates being developed for the both diagnosis as well as treatment of various cancers and non-cancer indications. The report covers marketed products details (Lutathera and Pluvito) and also candidates that are in various phases of development (Preclinical, Phase 1, Phase 2 & Phase 3). The pipeline focuses on diagnostic isotopes (Ga-68, Zr-89, Cu-64 and Pb-203) and therapeutic isotopes, (Ac-225, Pb-212, At-211, Ra-223, Th-227, Lu-177, Y-90, Re-188, Re-186, Cu-67, and Ho-166).
In case of Lu-177, Ga-68, Zr-89 and Cu-64, the report covers the patient population, treatment cost, total addressable market and penetration analysis for GEP-NET, Prostate cancer and Renal cancer. The pipeline analysis covers detailed analysis of name of candidates, list of companies, universities, and hospitals that are developing these agents, phase of development, nature of molecule, targets, and indications.
This report enables Pharmaceutical/Biotech companies, Academic institutes, Individual researchers, Investors, Medical technology companies, Service providers and other associated stake holders to identify and analyze the available licensing/collaborative commercial opportunities in the emerging isotopes global market. The report also provides strategic insights on some of the molecules which will eventually be launched in the next few years.
Market Analysis
In market analysis, global GEP-NET, Prostate cancer and Renal cancer market are indicated along with the Ga-68, Cu-64 and Zr-89 diagnostics market, and Lu-177, therapy market size, eligible patients pool, total addressable market (TAM), market penetration, opportunity and demand for Emerging Isotope is forecasted from 2020 to 2029.
Emerging Isotopes related deals analysis.
Global, N.A., Europe, APAC and RoW prevalence rates (GEP-NET, Prostate and Renal cancer).
Pipeline Analysis
Pipeline Analysis based Isotopes
Pipeline Analysis based on indications
Pipeline analysis based on targets
Pipeline analysis based on leading players
Key Players Analysis
The key player’s analysis section provides an in-depth understanding of various companies working on Emerging Isotopes and their pipelines with development phase as well as understanding partnering strategies such as deals entered by the company.
Key players overview
Key players Pipeline data (Pre-clinical, Phase 1, Phase 2 & Phase 3)
Key players deals (collaborations, partnership, licensing agreements, grants, funding etc.,)
Order this report: https://www.marketresearchreports.com/iq4i/emerging-isotopes-pipeline-analysis-and-global-market-forecast-2029
Browse more drug pipeline reports
For Tailor-made research services, please visit Custom Market Research.
About Market Research Reports, Inc.
Market Research Reports® Inc. is the world's largest store offering quality market research, SWOT analysis, competitive intelligence, and industry reports. We help Fortune 500 Start-Ups with the latest market research reports on global ®ional markets, which comprise key industries, leading market players, new products, and the latest industry analysis & trends.
Sudeep Chakravarty
Market Research Reports Inc.
+1 302-703-9904
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn
